

Cereno Scientific to present at BIO International Convention 2026 and advance global partnering discussions

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will participate in BIO International Convention 2026, taking place June 22–25, 2026, in San Diego, US. Cereno Scientific will also deliver a company presentation during the conference.

BIO International Convention is one of the world's largest and most comprehensive biotechnology events, bringing together more than 20,000 industry leaders from across the global biotech ecosystem. The event provides a premier platform for discussions with pharmaceutical companies, investors and strategic partners as Cereno Scientific continues to advance its HDAC inhibitor platform and clinical pipeline toward key value-inflection points.

"BIO International Convention is one of the most important global partnering events for the biotech industry. As we continue preparations for the start of the Phase IIb trial of CS1 and advance CS014 toward Phase II development, we look forward to engaging with pharmaceutical companies, investors and other stakeholders interested in innovative disease-modifying therapies for rare cardiovascular and pulmonary diseases. We believe our HDAC inhibitor platform represents a differentiated opportunity with the potential to address the underlying drivers of disease through epigenetic modulation," said Sten R. Sørensen, CEO of Cereno Scientific.

During the conference, Cereno Scientific will deliver a company presentation highlighting recent clinical progress, upcoming development milestones and the broader potential of the company's HDAC inhibitor platform.

Company presentation:

Presenter: Sten R. Sørensen, CEO

Date: Monday June 22, 2026

Time: 4:00 PM PT

Venue: Theater 4 at the San Diego Convention Center

Sten R. Sørensen, CEO, Rahul Agrawal, CMO & Head of R&D, and Jeppe Øvlesen, Chair of the Board, will attend the conference and participate in partnering meetings throughout the event. To book a meeting with Cereno Scientific, please contact

business.development@cerenoscientific.com or connect with the team via the BIO Partnering™ platform.

BIO is the world's largest advocacy association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 countries worldwide. The BIO International Convention is the organization's flagship event and a global forum for partnering, investment and innovation in biotechnology.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email: tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12-months treatment. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.